MARKET

PCRX

PCRX

Pacira BioSciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

61.60
-0.61
-0.98%
After Hours: 61.60 0 0.00% 16:11 05/17 EDT
OPEN
62.22
PREV CLOSE
62.21
HIGH
62.58
LOW
60.39
VOLUME
324.21K
TURNOVER
--
52 WEEK HIGH
80.00
52 WEEK LOW
40.96
MARKET CAP
2.71B
P/E (TTM)
18.57
1D
5D
1M
3M
1Y
5Y
Heron's Non-Opioid, Post-Operative Pain Drug Approved By FDA: Why This Is Important
Shares of Heron Therapeutics Inc (NASDAQ: HRTX) are higher after a long wait to get regulatory approval for its non-opioid pain drug.
Benzinga · 4d ago
Pacira Biosciences Inc (PCRX) CEO and Chairman David M Stack Sold $2.6 million of Shares
GuruFocus News · 4d ago
Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference
PARSIPPANY, May 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- PARSIPPANY, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today...
GlobeNewswire · 5d ago
Biondo Investment Advisors, LLC Buys Bed Bath & Beyond Inc, Boeing Co, Sells Vertex ...
GuruFocus News · 5d ago
Pacira BioSciences posts a five-fold rise in EXPAREL average daily sales in April
Pacira BioSciences (PACB) has announced $43.1M and $1.5M preliminary net product sales for EXPAREL (bupivacaine liposome injectable suspension) and iovera, respectively. During the month, EXPAREL average daily sales reached 449% of April
Seekingalpha · 6d ago
BRIEF-Pacira Biosciences Reports Preliminary Net Product Sales Of $44.6 Million For April 2021
reuters.com · 6d ago
Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021
April 2021 EXPAREL average daily sales were 449% of April 2020PARSIPPANY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions,...
GlobeNewswire · 6d ago
Pacira BioSciences Reports Decline in April Preliminary Net Product Sales
MT Newswires · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PCRX. Analyze the recent business situations of Pacira BioSciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PCRX stock price target is 80.08 with a high estimate of 94.00 and a low estimate of 54.00.
EPS
Institutional Holdings
Institutions: 387
Institutional Holdings: 53.99M
% Owned: 122.64%
Shares Outstanding: 44.03M
TypeInstitutionsShares
Increased
61
1.52M
New
23
918.28K
Decreased
78
1.54M
Sold Out
14
173.80K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.61%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Chief Executive Officer/Director
David Stack
President
Max Reinhardt
Chief Financial Officer
Charles Reinhart
Chief Administrative Officer/Secretary
Kristen Williams
Other
Charles Laranjeira
Other
Dennis McLoughlin
Other
Roy Winston
Lead Director/Independent Director
Paul Hastings
Director
Christopher Christie
Independent Director
Laura Brege
Independent Director
Mark Froimson
Independent Director
Yvonne Greenstreet
Independent Director
Mark Kronenfeld
Independent Director
John Longenecker
Independent Director
Gary Pace
Independent Director
Andreas Wicki
No Data
About PCRX
Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Webull offers kinds of Pacira Biosciences Inc stock information, including NASDAQ:PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.